Drugs / Biological/Vaccine: ET140203 autologous T-cell product
Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
Biological/Vaccine: ET140203 autologous T-cell product Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04634357 | Jul 2022 → Dec 2027 expected | hepatoblastoma, metastatic malignant neoplasm | Eureka Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biological/Vaccine: ET140203 autologous T-cell product Autologous T cells transduced with lentivirus encoding an ET140203 expression construct | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04634357 ↗ |
| Modality | Cell therapy | “Autologous T cells transduced with lentivirus encoding an ET140203 expression construct” NCT04634357 ↗ |
| Route | Intravenous | “safety of intravenous (IV) administration of ET140203 T cells” NCT04634357 ↗ |